1. Home
  2. APVO vs JXG Comparison

APVO vs JXG Comparison

Compare APVO & JXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.85

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Logo JX Luxventure Limited

JXG

JX Luxventure Limited

HOLD

Current Price

$3.90

Market Cap

7.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
APVO
JXG
Founded
2016
N/A
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
APVO
JXG
Price
$4.85
$3.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.8K
1.9K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
0.13
N/A
EPS
N/A
N/A
Revenue
$3,114,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.77
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.23
52 Week High
$13.11
$10.29

Technical Indicators

Market Signals
Indicator
APVO
JXG
Relative Strength Index (RSI) 46.89 50.58
Support Level $3.88 $3.74
Resistance Level $5.66 $3.94
Average True Range (ATR) 0.32 0.10
MACD -0.00 -0.01
Stochastic Oscillator 43.43 41.18

Price Performance

Historical Comparison
APVO
JXG

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

About JXG JX Luxventure Limited

JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.

Share on Social Networks: